Schedule a Meeting
Download Brochure
Table of Content
February 2025
The global asthma treatment market size is set to grow from USD 28.55 billion in 2025 to USD 38.57 billion by 2034, with an expected CAGR of 3.4% over the forecast period from 2025 to 2034, as a result of rising asthma prevalence and rising use of combination therapies.
Unlock Infinite Advantages: Subscribe to Annual Membership
Asthma-related deaths are more prevalent in low- and lower-middle-income countries due to challenges in under-diagnosis and under-treatment of the condition.
The asthma treatment market refers to the pharmaceuticals and devices used in the management and treatment of asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. The market encompasses a wide range of medications, inhalers, nebulizers, and other devices aimed at relieving symptoms, controlling inflammation, and preventing asthma attacks.
The market for asthma treatment is driven by several factors. Firstly, the increasing prevalence of asthma worldwide is a significant driver. Asthma affects millions of people globally, and the rising incidence of the disease fuels the demand for effective treatment options. Additionally, growing awareness and improved diagnosis of asthma contribute to market growth as more individuals seek appropriate treatment.
Advancements in asthma treatment technologies and innovations in drug delivery systems also drive market growth. Pharmaceutical companies are constantly developing new medications and inhalation devices with improved efficacy and convenience for patients.
The development of combination therapies that target different aspects of asthma management, such as bronchodilation and inflammation control, has also expanded treatment options. Furthermore, the growing focus on personalized medicine and tailored treatment approaches presents an opportunity for the asthma treatment market. Healthcare providers are increasingly emphasizing precision medicine to optimize asthma management based on an individual's specific characteristics and needs. This trend opens avenues for the development of targeted therapies and personalized treatment regimens.
The market for asthma treatment is geographically diverse, with significant opportunities in both developed and developing regions. In developed countries, the market is driven by well-established healthcare infrastructure, increased access to healthcare services, and higher awareness about asthma management. On the other hand, developing regions experience a growing demand for asthma treatment due to factors such as urbanization, environmental pollution, and lifestyle changes that contribute to the rise in asthma cases.
Artificial intelligence (AI) and machine learning (ML) algorithms are being developed to analyze large datasets and identify patterns and correlations in asthma management. These technologies can assist in predicting asthma exacerbations, optimizing treatment plans, and personalizing therapy based on individual patient characteristics. AI and ML enhance diagnostic accuracy and precision, ultimately reducing manual errors. AI-based tools can also aid in the interpretation of diagnostic tests, such as pulmonary function tests and imaging studies, facilitating faster and more accurate diagnosis. They significantly reduce the workload on healthcare professionals. AI and ML can also suggest personalized treatment regimens and predict treatment outcomes. Moreover, AI and ML can be used to develop novel therapeutics for asthma treatment, aiding in a faster drug discovery process.
Combination therapies play a significant role in the asthma treatment market. Asthma is a chronic condition that requires long-term management and control. Single medications may not always provide adequate symptom relief and disease control for all patients. Therefore, combination therapies, which involve the use of multiple medications with different mechanisms of action, have gained importance in asthma treatment. The use of combination therapies allows for more comprehensive control of asthma symptoms, reduction of exacerbations, and improvement in lung function. They are particularly beneficial for patients with moderate to severe asthma or those who do not respond well to monotherapy.
Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment, as they reduce airway inflammation. They are often combined with long-acting beta-agonists (LABA) to provide bronchodilation and improve symptom control. This combination is known as an ICS/LABA therapy and is commonly prescribed as a maintenance treatment for asthma. In addition to ICS/LABA combinations, other combination therapies may include the use of leukotriene modifiers, mast cell stabilizers, or long-acting muscarinic antagonists (LAMA) in conjunction with ICS or LABA. These combinations target different aspects of asthma pathophysiology to achieve better control and management of the disease.
The growing adoption of combination therapies in asthma treatment is driven by the need for personalized and tailored approaches to patient care. Each patient's asthma condition is unique, and a one-size-fits-all approach may not be sufficient. Combination therapies allow healthcare providers to customize treatment regimens based on individual patient needs, symptom severity, and treatment response. Furthermore, combination therapies can help simplify treatment regimens and improve patient adherence. Rather than prescribing multiple medications separately, combining them into a single inhaler or fixed-dose combination product can make treatment more convenient and easier for patients to follow.
The availability of various combination therapies has expanded the treatment options for healthcare providers, offering more choices to optimize asthma management. It has also stimulated competition among pharmaceutical companies, leading to ongoing research and development efforts to develop new and improved combination therapies. Thus, combination therapies are a vital component of the asthma treatment market. They provide comprehensive symptom control, improved disease management, and personalized treatment approaches for patients with asthma. The continued development and utilization of combination therapies contribute to advancements in asthma care and better outcomes for individuals living with this chronic respiratory condition.
The rising incidence of asthma is a key driving factor for the growth of the asthma treatment market. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, coughing, and chest tightness. It affects people of all ages, from children to adults, and its prevalence has been increasing globally.
There are several reasons behind the rising incidence of asthma. Environmental factors such as exposure to air pollution, allergens, and tobacco smoke contribute to the development of asthma. Changes in lifestyle, including sedentary habits, unhealthy diets, and increased urbanization, also play a role. Additionally, genetic and hereditary factors can predispose individuals to asthma.
The increasing prevalence of asthma has created a significant demand for effective asthma treatments. Healthcare providers and pharmaceutical companies are investing in research and development to discover new therapies and improve existing treatments. This includes the development of inhalation medications, oral medications, and biologics targeting specific pathways involved in asthma pathogenesis.
The high cost of asthma treatment is a significant factor that impacts the asthma treatment market. The cost of medications, including inhalers and oral medications, can be a burden for many patients, especially those without adequate insurance coverage or who are in low-income populations. The high cost of treatment can limit access to necessary medications and preventive measures, leading to suboptimal asthma management. One of the reasons for the high cost of asthma treatment is the development and manufacturing process of medications. Research and development, clinical trials, and regulatory approvals add to the overall cost. Additionally, the continuous need for innovation and the introduction of newer, more effective medications also contribute to the high cost.
The high cost of treatment can result in challenges for patients in affording their medications and can lead to medication non-adherence. This, in turn, can lead to inadequate symptom control, increased risk of exacerbations, and the need for emergency care, which further escalates healthcare costs. The impact of high treatment costs extends beyond individual patients to healthcare systems as a whole. The economic burden of asthma treatment includes direct healthcare costs, such as medication expenses, hospitalizations, and emergency room visits, as well as indirect costs associated with productivity losses due to missed work or decreased work efficiency.
Efforts are being made to address the high cost of asthma treatment. Generic versions of some asthma medications have become available, which can help reduce costs. Pharmaceutical companies, healthcare organizations, and policymakers are also exploring strategies such as price negotiations, formulary management, and value-based pricing to make asthma medications more affordable and accessible. Furthermore, patient assistance programs, drug discount cards, and subsidies are being implemented to support individuals who face financial barriers to accessing asthma treatment. Awareness campaigns and educational initiatives are also important in helping patients understand the available options for managing their asthma and finding cost-effective solutions.
Reducing the high cost of asthma treatment requires a multi-faceted approach involving various stakeholders, including healthcare providers, pharmaceutical companies, insurers, policymakers, and patient advocacy groups. Collaborative efforts are needed to find innovative solutions that ensure affordable access to effective asthma treatments, ultimately improving patient outcomes and reducing the economic burden associated with asthma.
The field of asthma treatment is experiencing a significant transformation driven by technological advancements, which are creating new opportunities to enhance patient care and improve treatment outcomes. Innovative solutions leveraging technology are revolutionizing asthma management, providing better tools for diagnosis, monitoring, and personalized treatment.
Digital health platforms including mobile applications and web-based tools, are empowering patients to actively manage their asthma. These platforms provide features such as symptom tracking, medication reminders, and personalized action plans. They also enable patients to communicate with healthcare providers, facilitating remote monitoring and timely interventions. Digital health platforms enhance patient engagement, improve adherence to treatment plans, and enable data-driven decision-making.
In addition, smart inhalers are inhalation devices equipped with sensors that capture data on medication usage, inhalation technique, and environmental factors. These devices help patients monitor their inhaler usage, providing feedback on proper inhalation techniques and adherence to prescribed treatment. Smart inhalers can also send data to healthcare providers, enabling remote monitoring and proactive interventions based on real-time information. Furthermore, wearable devices, such as smartwatches and activity trackers, are increasingly being used to monitor asthma symptoms and related physiological parameters. These devices can track respiratory rate, heart rate, physical activity, and sleep patterns, providing valuable insights into asthma control and triggers. By collecting continuous data, wearable devices offer a holistic view of a patient's health and enable personalized treatment adjustments.
Telemedicine platforms and remote monitoring technologies allow patients to have virtual consultations with healthcare providers, reducing the need for in-person visits. Remote monitoring devices can measure lung function, oxygen levels, and other vital signs, enabling healthcare professionals to monitor asthma control and adjust treatment plans as needed. Telemedicine and remote monitoring enhance access to care, particularly for patients in rural or underserved areas.
By drug class, the anti-inflammatory segment held a dominant presence in the asthma treatment market in 2024. Anti-inflammatory class of drugs and steroids are commonly prescribed for asthma. These drugs act by reducing inflammation, swelling, and mucus production in the airways. The primary benefit of these drugs includes fast relief as they reduce the symptoms of the disease. Additionally, they help to stop the process that leads to asthma attacks. They are comparatively safer and cost-effective, leading to enhanced medication adherence. They are administered through the inhalation route to aid in targeted therapy and result in a reduced number of hospitalizations for life-threatening asthma.
By drug class, the combination therapy segment is anticipated to grow with the highest CAGR in the market during the studied years. Combination therapy is an emerging treatment of choice for healthcare professionals as it helps to cure asthma from different aspects simultaneously. Some common examples of combination therapies include fluticasone and salmeterol, budesonide and formoterol, and mometasone and formoterol. This reduces the number of medications to be taken by a patient, increasing medication adherence. Combination therapy also reduces the complexity of the treatment and morbidity associated with the disease.
By product, the inhalers segment held the largest share of the asthma treatment market in 2024. Inhalers are small, handheld devices that deliver medicines directly to the lungs through the mouth. They are small, portable, and easy to use, making them a preferable choice for a wide range of populations. The advent of advanced technologies drives the latest innovations in inhalers, enhancing patient experience and aiding in accurate dosing. Inhalers comparatively take less time to deliver medicines to the lungs, leading to fewer side effects.
By product, the nebulizers segment is projected to expand rapidly in the market in the coming years. Nebulizers are devices that convert liquid medications into a fine mist to deliver through the lungs. They are easy to use and can deliver multiple medicines at a time, potentiating the segment’s growth. There are three types of nebulizers: jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The type of nebulizer to be used depends on a patient’s medical conditions. Advancements in technology have led to the development of novel and more advanced smart nebulizer devices to automate the delivery of drugs.
By route of administration, the inhaled segment led the global asthma treatment market in 2024. The inhalation route offers numerous benefits, including direct delivery of medications to the targeted site (e.g., lungs), rapid onset of action, and reduced systemic side effects. It is more versatile and can be used for a wide range of medications. It reduces the side effects of oral and parenteral administration, such as bad taste and infection at the injection site, and increases medication adherence. The inhalation route is preferred by people of all age groups.
By route of administration, the oral segment is expected to grow at the fastest rate in the market during the forecast period of 2024 to 2034. The demand for oral routes is increasing, owing to ease of use, cost-effectiveness, and patient compliance. They have the advantage of being administered through noninvasive routes, potentiating convenience. Additionally, it is the safest route of administration and favors ease of ingestion.
North America dominates the asthma treatment market due to several factors. The region has a relatively higher prevalence of asthma compared to other parts of the world. According to the Asthma and Allergy Foundation of America report, asthma affects nearly 28 million people in the U.S., accounting for 1 in 12 people. The prevalence of asthma underscores its significant impact on public health and emphasizes the need for effective management strategies and access to proper healthcare services.
Children below the age of 18 are also prone to asthma in the U.S., amounting to around 4.9 million cases as of September 2024. This statistic highlights the significant burden of asthma on children and the importance of proactive management and preventive measures to reduce the frequency and severity of asthma attacks. Asthma attacks can be distressing and potentially life-threatening, so it is crucial to ensure proper asthma control, regular medical care, and appropriate use of medications to minimize the risk and impact of these attacks on children's health and well-being.
The dominance of North America in the asthma treatment market can also be attributed to advanced healthcare infrastructure, well-established pharmaceutical companies, and extensive research and development activities in the region. The United States, in particular, has a robust healthcare system and a high level of healthcare expenditure, which supports the availability and accessibility of asthma treatment options.
In addition, North America is home to several key players in the pharmaceutical industry that specialize in the development and manufacturing of asthma medications. These companies have a strong presence in the region and contribute to the development of innovative therapies for asthma management. Furthermore, the region has a well-developed regulatory framework for drug approvals and a favorable reimbursement system, which encourages the adoption of asthma treatments. This ensures that patients have access to a wide range of medications and treatment options.
Moreover, North America also has a strong focus on asthma research and clinical trials. Academic institutions, research centers, and healthcare organizations in the region actively participate in studies to explore new treatment approaches, evaluate the effectiveness of existing therapies, and improve patient outcomes.
Asia-Pacific is projected to host the fastest-growing market in the coming years. The rising prevalence of asthma, primarily due to air pollution, smoking, and sedentary lifestyles, is a significant growth factor in the market. The prevalence rate of asthma in China is 1.1% to 11% annually. India contributes to 12.9% of global asthma cases, accounting for 35 million people suffering from asthma in 2023. The growing research and development activities, increasing investments, collaborations, and mergers & acquisitions drive the market. Favorable government initiatives for screening, early detection, and treatment also contribute to the market. The rapidly expanding healthcare sector, with the rising adoption of advanced technology, leads to enhanced patient treatment in Asia-Pacific. Moreover, treatment costs in several Asia-Pacific countries are affordable, attracting people from foreign countries for effective treatment.
In July 2024, GlaxoSmithKline and Flagship announced a collaboration to develop up to 10 new drugs and vaccines for treating respiratory and immunological disorders. Tony Wood, PhD, CSO of GSK, commented that the collaboration would be used to deliver best-in-class innovation at pace. He also said that the collaboration would help to accelerate their pipeline and discover practice-changing medicines and vaccines for patients.
By Drug Class
By Product
By Route of Administration
By Region
February 2025
February 2025
February 2025
February 2025
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts